D-003, a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 67, Issue 1, 2002, Pages 19-24

  Molina, V ^a   Arruzazabala, M L ^a   Carbajal, D ^a   Mas R ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ALIPHATIC CARBOXYLIC ACID; ANTICOAGULANT AGENT; ARACHIDONIC ACID DERIVATIVE; COLLAGEN; D 003; DOTRIACONTANOIC ACID; FATTY ACID DERIVATIVE; MALONALDEHYDE; NATURAL PRODUCT; OCTACOSANOIC ACID; PROSTACYCLIN; TETRATRIACONTANOIC ACID; THROMBOXANE A2; THROMBOXANE B2; TRIACONTANOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTERY THROMBOSIS; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG PURITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE STRUCTURE; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ARUNDINARIA; SACCHARUM;

EID: 0036661282     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2002.0376     Document Type: Article

References (42)

1. Packman, M. A., Mustard J. F. The role of platelets in the development and complications of atherosclerosis. Sem Haematol 1981; 23: 8.
2. Wilson J. M., Ferguson J. J. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol 1999; 23: 687-698.
3. Grand R. Platelet activation and arterial thrombosis. Lancet 1994; 344: 991-994.
4. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials antiplatelet therapy I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
5. Gent M. Ticlopidine after completed thromboembolic stroke. The Canadian American Ticlopidine Study (CATS) Ticlopidine Satellite Symposium, Ljubljana, Yugoeslavia, 1990; 8-11.
6. CAPRIE Steering Committee. A randomized, blinded trial of clopidrogel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
7. Lanas A. I., Arroyo M. T., Esteva F., Cornudella R., Hirschowitz B. T., Sainz R. Aspirin related gastrointestinal bleeders have an exaggerated bleeding rime response due to aspirin use. Gut 1996; 39 (5): 654-660.
8. Creager M. A. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Copidrogel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3 (3): 257-260.
9. Harbison J. W. Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease. Am J Health Syst Pharm 1998; 55: S17-S20.
10. Svensson J., Hamberg M., Samuelsson B. On the formation and effects of thromboxane A2 in human platelets. Acta Physiol Scand 1975; 94: 222-228.
11. Moncada, S., Herman A. G., Higgs E. A., Vane J. R. Differential formation of prostacyclin (PgX or Pg12) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Throm Res 1977; 11: 323-344.
12. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
13. Gryglewski R. J., Bunting S., Moncada S., Flower R. J., Vane J. R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 1976; 12: 685-713.
14. Bunting S., Gryglewski R. J., Moncada S., Vane J. R. Arterial walls generate from prostaglandin endoperoxides a substance which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913.
15. Moncada S., Gryglewski R. J., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
16. Yamanobe S., Nakagawa Y., Hishinuma T., Mizugaki M., Tamai M. Analysis of urinary 11-dehydrothromboxane B2 in patients with occluded retinal vein using GC/SIM. Prostaglandins Leukot Essent Fatty Acids 1998; 58 (1): 65-68.
17. Serebruany V. L., Herzog W. R., Edenbaum L. R., Shustov A. R., Gurbel P. A. Changes in the haemostatic profile during magnesium deficiency in swine. Magnes Res 1996; 9 (3):155-163.
18. Mori T. A., Beilin L. J., Burke V., Morris J., Ritchie J. Interactions between dietary fat, fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Bio 1997; 17 (2): 279-286.
19. González L., Marrero D., Laguna A., Más R., Arruzazabala M. L., Carbajal D., Cora M., Menéndez R. A mixture of primary fatty acids obtained from sugar carie wax, Laboratorios DALMER S.A., CU35/97.
20. Molina V., Arruzazabala M. L., Carbajal D., Más R., Valdés S. Antiplatelet and antithrombotic effects of D-003. Pharmacol Res 2000; 42 (2): 137-143.
21. Gámez R., Mendoza S., Más R., Mesa R., Castaño G., Marrero D. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits Curr Ther Res 2000; 61: 8-16.
22. Gámez R., Mas R., Noa M., Menéndez R., et al. Acute and oral subchronic toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31-41.
23. Kimura Y., Tani T., Kaube T., Watanabe K. Effect of celostagol on platelet aggregation and experimental thrombosis. Arzneim Forsch Drug Res 1985; 35: 1144-1148.
24. Herbert J. M., Bernat A., Maffrand J. P. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80 (9): 2281-2286.
25. 2. Thromb Res 1982; 26: 389-400.
26. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
27. Hladovec J. A sensitive model of venous thrombosis in rats. Thromb Res 1986; 43: 539-544.
28. Manley P. W., Tuffin D. P., Allanson N. M., et al. Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R), (S), and ± 2,2 dimethyl-6-[2-(1-Hi-midazol-1-yl)-1-[[(4-methoxyphenyl)-methoxy]methyl] ethoxy]hexanoic acids. J Med Chem 1987; 30: 1812-1818.
29. Vermylen J., Deckmyn H. Reorientation of prostaglandin endoperoxides metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. Br J Clin Pharmacol 1983; 15: 17s-22s.
30. Bassenge E. Endothelial function in different organs. Progress Cardiovasc Dis 1996; XXXIX: 209-228.
31. Pignatelli P., Pulcenelli F. M., Lenti L., Gazaniga P. P., Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91 (2): 484-490.
32. 2 to hydrolyze membrane phospholipids in rabbit platelets. J Biochem 1997; 122: 859-864.
33. Iuliano L., Colavita A. R., Leo R., Pratico D., Violi F. Oxigen free radicals and platelet activation. Free Rad Biol Med 1997; 22: 999.
34. Moncada S., Gryglewski R. J., Bunting S., Vane J. R. A lipid peroxide inhibits the enzymes in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 1976; 12: 715-733.
35. Gryglewski R. J., Palmer R. M. J., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-456.
36. Kohler C., Wooding W., Ellenbager L. Intravenous arachidonate in the mouse. A model for the evaluation of the antithrombotic drugs. Thromb Res 1978; 9: 67.
37. Silver M. J., Hoch W., Kocsis J. J., Ingerman C. M., Smith J. B. Arachidonic acid causes death in rabbits. Science 1974; 183: 1085.
38. 2 during arachidonate infusion in rabbits. Thromb Res 1978; 12: 549.
39. 2 and 6-keto PgF1alpha synthesis during infusion of collagen and arachidonic acid in rabbits. Inhibition by aspirin and sulfinpyrazone. Thromb Res 1980; 18: 693.
40. Seuter F., Scriabine A. Platelets and platelet aggregation inhibitors. In: Antonaccio M. (Ed.) Cardiovascular Pharmacology. New York: Raven Press, 1984; 475-518.
41. Adaikan P. G., Loganath A., Karim S. M. M., Ratnam S. S. Antiplatelet drugs with emphasis on prostanoids. Asia Pacific J Pharmacol 1987; 2: 61-78.
42. Chabielska E., Pawlak R., Golatowski J., Rolkowski R., Pawlak D., Buczko W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res 1998; 90 (6): 271-278.